Skip to main content

$0.026 (0%)

High

$0.03

Low

$0.02

Trades

28

Turnover

$17,745

Volume

720,270
30 June 2023 at 4:10pm
Register to track HYD and receive email alerts.
Subject
HYD Ann: Notification of cessation of securities - HYD

HYD Ann: Ceasing to be a substantial holder

HYD Ann: Change in substantial holding

HYD Ann: Notification of cessation of securities - HYD

HYD Ann: Notification of cessation of securities - HYD

HYD Ann: Annual General Meeting and Director Nomination Closing Date

HYD Ann: Application for quotation of securities - HYD

HYD Ann: Cleansing Notice

HYD Ann: Appendix 2A

HYD Ann: Hydrix On Track for Cardiac Product Sales in H1 CY22

HYD Ann: MEM: Reaches settlement agreement with Hydrix

HYD Ann: FY2021 Letter from Executive Chairman

HYD Ann: FY2021 Appendix 4E and Financial Report

HYD Ann: Proposed issue of securities - HYD

HYD Ann: Commercial arrangement between Hydrix and Memphasys

HYD Ann: Application for quotation of securities - HYD

HYD Ann: Notification of cessation of securities - HYD

HYD Ann: Notification of cessation of securities - HYD

HYD Ann: Application for quotation of securities - HYD

HYD Ann: AngelMed completes its first USA commercial Guardian implant

HYD Ann: Quarterly Activities Report and Appendix 4C

HYD Ann: Application for quotation of securities - HYD

HYD Ann: Hydrix completes TGA submission for AngelMed Guardian System

HYD Ann: Ceasing to be a substantial holder

HYD Ann: Investor Presentation - AngelMed Guardian FDA Approval

HYD Ann: AngelMed receives FDA approval for Guardian upgraded battery

HYD Ann: Trading halt

HYD Ann: Change in substantial holding

HYD Ann: Appendix 2A

HYD Ann: Quarterly Activities Report and Appendix 4C

HYD Ann: Change in substantial holding

HYD Ann: Hydrix Medical - Business Update

HYD Ann: Appendix 2A

HYD Ann: Half Year Trading Update

HYD Ann: Appendix 4D and Half-Yearly Report

HYD Ann: Appendix 2A

HYD Ann: Quarterly Activities Report and Appendix 4C

HYD Ann: Appendix 2A

HYD Ann: Appendix 3Y x 2

HYD Ann: Becoming a substantial holder

HYD Ann: Cleansing Notice

HYD Ann: Appendix 2A - Tranche 2 Placement

HYD Ann: Appendix 2A - Exercise of Options

HYD Ann: Appendix 2A - vesting of LTIP performance rights

HYD Ann: Appendix 3G

HYD Ann: Results of 2020 AGM

HYD Ann: 2020 AGM - Executive Chairman's Presentation

HYD Ann: First in human trials of Phyzhon Health PHYRARI FFR-WIRE

HYD Ann: Appendix 2A

HYD Ann: Appendix 2A

Register to track HYD and receive email alerts.

Similar Companies

AVA
CAT
CDA
CT1
HTG
NVX
RDF
SMN
SPZ